About US
Contact us
-
Pharma execs, upset by Trump's drug pricing executive orders, refuse White House meetingPresident Donald Trump seems to have hit a nerve with his Friday executive orders on drug pricing. As drug companies work to battle the pandemic, executives declined to attend a White House meeting t2020/7/28
-
AstraZeneca's Farxiga backs up kidney disease trial stop with new top-line dataAstraZeneca has shaken upthe lucrative heart failure market with diabetes med Farxiga after a major approval earlier this year. But in kidney disease, another blockbuster market, Farxiga also sports2020/7/27
-
Pfizer could earn $15B-plus in COVID-19 vaccine sales: analystOn the heels of Pfizer's $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program2020/7/27
-
Pfizer, BioNTech's U.S. supply deal price tag leaves room for 'decent' profit on COVID-19 shot: analystThe Trump administration made a major splash in the race for a COVID-19 vaccine this week with its $1.95 billion supply deal for Pfizer and BioNTech's shot. With 100 million doses due in the deal, th2020/7/24
-
Novartis, Regeneron wage acrimonious patent fight over Eylea's prefilled syringeRegeneron’s prefilled Eylea syringe has gained fast traction since its introduction in late 2019. But the new delivery method forthe eye med has drawn ire from Novartis, co-developer of rival Lucenti2020/7/24
-
Jazz’s Xywav, a low-sodium alternative to blockbuster Xyrem, snags FDA nod in narcolepsyJazz Pharmaceuticals’ Xyrem has become the standard of care for two symptoms of narcolepsy since its FDA approval in 2002. But the company’s introducing a sister drug that potentially offers better h2020/7/23
-
Biogen unexpectedly replaces CFO Capello with IQVIA vet, sparking M&A speculationWhen Biogen appointed Jeffrey Capello as its new chief financial officer in late 2017, CEO Michel Vounatsos said he would be key to the company’s efforts to seek out new business development opportun2020/7/23
-
FDA rails at California CDMO for failing to secure data used to determine strength of its drugsGenerally speaking, the quality of a manufacturer's data is only as good as the policies in place to ensure the information. Allowing all employees to access those data files—and even possibly delete2020/7/22
-
Biogen's lagging Vumerity, stalled by the pandemic, faces 'critical' stretch ahead, CEO saysBiogen’s Tecfidera follow-up Vumerity hitthe marketlate lastyear, but eight months into the launch, the new multiple sclerosis drug isyet to meaningfully take off. The druggeneratedonly $11 million i2020/7/22
-
Pfizer, BioNTech snare $1.95B deal with U.S. government for 100M-plus doses of COVID-19 vaccineThe Trump administration's Warp Speed initiative has placed its biggest bet yet on an accelerated COVID-19 vaccine—and Pfizer and BioNTech are the lucky recipients. The vaccine partnerslandedan initi2020/7/21